References

1. Menezes da Silveira, C.C.; Luz, D.A.; da Silva, C.C.; Prediger, R.D.; Martins, M.D.; Martins, M.A.; Fontes-Júnior, E.A.; Maia, C.S. Propolis: A useful agent on psychiatric and neurological disorders? A focus on CAPE and pinocembrin components. Med. Res. Rev. 2020.
2. Ağrı, İ.; Erdal Ağrı, A.; Özdemir, D.; Özgür, A. Chapter 31—CAPE and Tympanosclerosis. In Polyphenols: Mechanisms of Action in Human Health and Disease, 2nd ed.; Watson, R.R., Preedy, V.R., Zibadi, S., Eds.; Academic Press: Amsterdam, The Netherlands; Elsevier: Amsterdam, The Netherlands, 2018; pp. 421–430.
3. Sforcin, J.M.; Bankova, V. Propolis: Is there a potential for the development of new drugs? J. Ethnopharmacol. 2011, 133, 253–260.
4. Toreti, V.C.; Sato, H.H.; Pastore, G.M.; Park, Y.K. Recent progress of propolis for its biological and chemical compositions and its botanical origin. Evid.-Based Complement. Altern. Med. 2013, 2013, 1–13.
5. Grunberger, D.; Banerjee, R.; Eisinger, K.; Oltz, E.M.; Efros, L.; Caldwell, M.; Estevez, V.; Nakanishi, K. Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis. Cell. Mol. Life Sci. 1988, 44, 230–232.
6. Akyol, S.; Armutcu, F.; Yigitoglu, M. The medical usage of caffeic acid phenethyl ester (CAPE), an active compound of propolis, in neurological disorders and emergencies. Spatula DD 2011, 1, 37–42.
7. Göçer, H.; Gülçin, İ. Caffeic acid phenethyl ester (CAPE): Correlation of structure and antioxidant properties. Int. J. Food Sci. Nutr. 2011, 62, 821–825.
8. Celli, N.; Dragani, L.K.; Murzilli, S.; Pagliani, T.; Poggi, A. In Vitro and in vivo stability of caffeic acid phenethyl ester, a bioactive compound of propolis. J. Agric. Food Chem. 2007, 55, 3398–3407.
9. Tolba, M.F.; Azab, S.S.; Khalifa, A.E.; Abdel-Rahman, S.Z.; Abdel-Naim, A.B. Caffeic acid phenethyl ester, a promising component of propolis with a plethora of biological activities: A review on its anti-inflammatory, neuroprotective, hepatoprotective, and cardioprotective effects. IUBMB Life 2013, 65, 699–709.
10. Murtaza, G.; Karim, S.; Akram, M.R.; Khan, S.A.; Azhar, S.; Mumtaz, A.; Bin Asad, M.H.H. Caffeic acid phenethyl ester and therapeutic potentials. BioMed Res. Int. 2014, 2014.
11. Ali, M.A.; Menze, E.T.; Tadros, M.G.; Tolba, M.F. Caffeic acid phenethyl ester counteracts doxorubicin-induced chemobrain in Sprague-Dawley rats: Emphasis on the modulation of oxidative stress and neuroinflammation. Neuropharmacology 2020, 181, 108334.
12. Çetin, A.; Deveci, E. Evaluation of PECAM-1 and p38 MAPK expressions in cerebellum tissue of rats treated with caffeic acid phenethyl ester: A biochemical and immunohistochemical study. Folia Morphol. 2019, 78, 221–229.
13. Eşrefoğlu, M.; Gül, M.; Ateş, B.; Yılmaz, İ. The ultrastructural and biochemical evidences of the beneficial effects of chronic caffeic acid phenethyl ester and melatonin administration on brain and cerebellum of aged rats. Fundam. Clin. Pharmacol. 2010, 24, 305–315.
14. Amodio, R.; De Ruvo, C.; Di Matteo, V.; Poggi, A.; Di Santo, A.; Martelli, N.; Lorenzet, R.; Rotilio, D.; Cacchio, M.; Esposito, E. Caffeic acid phenethyl ester blocks apoptosis induced by low potassium in cerebellar granule cells. Int. J. Dev. Neurosci. 2003, 21, 379–389.
15. Ilhan, A.; Iraz, M.; Gurel, A.; Armutcu, F.; Akyol, O. Caffeic acid phenethyl ester exerts a neuroprotective effect on CNS against pentylenetetrazol-induced seizures in mice. Neurochem. Res. 2004, 29, 2287–2292.
16. Lin, M.-W.; Yang, S.-R.; Huang, M.-H.; Wu, S.-N. Stimulatory actions of caffeic acid phenethyl ester, a known inhibitor of NF-κB activation, on Ca2+-activated K+ current in pituitary GH3 cells. J. Biol. Chem. 2004, 279, 26885–26892.
17. Yiş, U.; Topçu, Y.; Özbal, S.; Tuğyan, K.; Bayram, E.; Karakaya, P.; Yilmaz, O.; Kurul, S.H. Caffeic acid phenethyl ester prevents apoptotic cell death in the developing rat brain after pentylenetetrazole-induced status epilepticus. Epilepsy Behav. 2013, 29, 275–280.
18. Wei, X.; Ma, Z.; Fontanilla, C.; Zhao, L.; Xu, Z.; Taggliabraci, V.; Johnstone, B.; Dodel, R.; Farlow, M.; Du, Y. Caffeic acid phenethyl ester prevents cerebellar granule neurons (CGNs) against glutamate-induced neurotoxicity. Neuroscience 2008, 155, 1098–1105.
19. dos Santos, N.A.G.; Martins, N.M.; de Barros Silva, R.; Ferreira, R.S.; Sisti, F.M.; dos Santos, A.C. Caffeic acid phenethyl ester (CAPE) protects PC12 cells from MPP+ toxicity by inducing the expression of neuron-typical proteins. Neurotoxicology 2014, 45, 131–138.
20. Montpied, P.; de Bock, F.; Rondouin, G.; Niel, G.; Briant, L.; Courseau, A.-S.; Lerner-Natoli, M.; Bockaert, J. Caffeic acid phenethyl ester (CAPE) prevents inflammatory stress in organotypic hippocampal slice cultures. Mol. Brain Res. 2003, 115, 111–120.
21. Choi, K.; Choi, C. Differential regulation of c-Jun N-terminal kinase and NF-κB pathway by caffeic acid phenethyl ester in astroglial and monocytic cells. J. Neurochem. 2008, 105, 557–564.
22. Singh, J.; Khan, M.; Singh, I. Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes. Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids 2013, 1831, 747–758.
23. Ilhan, A.; Akyol, O.; Gurel, A.; Armutcu, F.; Iraz, M.; Oztas, E. Protective effects of caffeic acid phenethyl ester against experimental allergic encephalomyelitis-induced oxidative stress in rats. Free Radic. Biol. Med. 2004, 37, 386–394.
24. Barber, S.C.; Higginbottom, A.; Mead, R.J.; Barber, S.; Shaw, P.J. An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radic. Biol. Med. 2009, 46, 1127–1138.
25. Fontanilla, C.; Wei, X.; Zhao, L.; Johnstone, B.; Pascuzzi, R.; Farlow, M.; Du, Y. Caffeic acid phenethyl ester extends survival of a mouse model of amyotrophic lateral sclerosis. Neuroscience 2012, 205, 185–193.
26. Tsai, C.-F.; Kuo, Y.-H.; Yeh, W.-L.; Wu, C.Y.-J.; Lin, H.-Y.; Lai, S.-W.; Liu, Y.-S.; Wu, L.-H.; Lu, J.-K.; Lu, D.-Y. Regulatory effects of caffeic acid phenethyl ester on neuroinflammation in microglial cells. Int. J. Mol. Sci. 2015, 16, 5572–5589.
27. Noelker, C.; Bacher, M.; Gocke, P.; Wei, X.; Klockgether, T.; Du, Y.; Dodel, R. The flavanoide caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity. Neurosci. Lett. 2005, 383, 39–43.
28. Ma, Z.; Wei, X.; Fontanilla, C.; Noelker, C.; Dodel, R.; Hampel, H.; Du, Y. Caffeic acid phenethyl ester blocks free radical generation and 6-hydroxydopamine-induced neurotoxicity. Life Sci. 2006, 79, 1307–1311.
29. Silva, R.B.; Santos, N.; Martins, N.; Ferreira, D.; Barbosa, F., Jr.; Souza, V.O.; Kinoshita, A.; Baffa, O.; Del-Bel, E.; Santos, A. Caffeic acid phenethyl ester protects against the dopaminergic neuronal loss induced by 6-hydroxydopamine in rats. Neuroscience 2013, 233, 86–94.
30. Kurauchi, Y.; Hisatsune, A.; Isohama, Y.; Mishima, S.; Katsuki, H. Caffeic acid phenethyl ester protects nigral dopaminergic neurons via dual mechanisms involving haem oxygenase-1 and brain-derived neurotrophic factor. Br. J. Pharmacol. 2012, 166, 1151–1168.
31. Zaitone, S.A.; Ahmed, E.; Elsherbiny, N.M.; Mehanna, E.T.; El-Kherbetawy, M.K.; ElSayed, M.H.; Alshareef, D.M.; Moustafa, Y.M. Caffeic acid improves locomotor activity and lessens inflammatory burden in a mouse model of rotenone-induced nigral neurodegeneration: Relevance to Parkinson’s disease therapy. Pharmacol. Rep. 2019, 71, 32–41.
32. Deveci, H.A.; Karapehlivan, M. Chlorpyrifos-induced parkinsonian model in mice: Behavior, histopathology and biochemistry. Pestic. Biochem. Physiol. 2018, 144, 36–41.
33. Fontanilla, C.; Ma, Z.; Wei, X.; Klotsche, J.; Zhao, L.; Wisniowski, P.; Dodel, R.; Farlow, M.; Oertel, W.; Du, Y. Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration. Neuroscience 2011, 188, 135–141.
34. Kumar, M.; Bansal, N. Caffeic acid phenethyl ester rescued streptozotocin-induced memory loss through PI3-kinase dependent pathway. Biomed. Pharmacother. 2018, 101, 162–173.
35. Kumar, M.; Kaur, D.; Bansal, N. Caffeic acid phenethyl ester (CAPE) prevents development of STZ-ICV induced dementia in rats. Pharmacogn. Mag. 2017, 13, S10.
36. Morroni, F.; Sita, G.; Graziosi, A.; Turrini, E.; Fimognari, C.; Tarozzi, A.; Hrelia, P. Neuroprotective effect of caffeic acid phenethyl ester in a mouse model of Alzheimer’s disease involves Nrf2/HO-1 pathway. Aging Dis. 2018, 9, 605.
37. Ozyurt, B.; Ozyurt, H.; Akpolat, N.; Erdogan, H.; Sarsilmaz, M. Oxidative stress in prefrontal cortex of rat exposed to MK-801 and protective effects of CAPE. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31, 832–838.
38. Celik, S.; Erdogan, S. Caffeic acid phenethyl ester (CAPE) protects brain against oxidative stress and inflammation induced by diabetes in rats. Mol. Cell. Biochem. 2008, 312, 39–46.
39. Korish, A.A.; Arafa, M.M. Propolis derivatives inhibit the systemic inflammatory response and protect hepatic and neuronal cells in acute septic shock. Braz. J. Infect. Dis. 2011, 15, 332–338.
40. Fadillioglu, E.; Gursul, C.; Iraz, M. Effects of caffeic acid phenethyl ester on thioacetamide-induced hepatic encephalopathy in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2010, 34, 1440–1445.
41. Jia, Y.; Jiang, S.; Chen, C.; Lu, G.; Xie, Y.; Sun, X.; Huang, L. Caffeic acid phenethyl ester attenuates nuclear factor-κB-mediated inflammatory responses in Müller cells and protects against retinal ganglion cell death. Mol. Med. Rep. 2019, 19, 4863–4871.